Cite
MLA Citation
T S K Mok et al.. “LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC).” Annals of oncology, vol. 29, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100095508195.0x00002d